Ionis says diranersen slows clinical decline in early Alzheimer’s at two years
IONS•Ionis Pharmaceuticals said diranersen slowed cognitive and functional decline over two years in the Phase 2 CELIA trial. The 60 mg twice-yearly regimen showed the largest effects, and no new safety signals were observed.
1. Two-year trial results
Ionis Pharmaceuticals reported increasing clinical benefit from investigational diranersen in early Alzheimer’s disease over two years in the Phase 2 CELIA trial. The 60 mg twice-yearly regimen showed the largest effects; the analysis compared continued treatment with participants initially assigned placebo who received little or no diranersen during the open-label extension. Diranersen was generally well tolerated, with no new safety signals observed.




